Physician profile
Jamiel J Ambrad
NPI 1720076011
$17,999.50
in general payments reported to CMS, 2019-2025
43 companies · $3,683 in 2025
The $3,683 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,255 · 2021: $1,991 · 2022: $2,514 · 2023: $3,324 · 2024: $3,279 · 2025: $3,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,286.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,960.15 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $2,535.40 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Novo Nordisk INC | $1,441.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,360.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $863.02 | 2021-2025 | Trulance, Xifaxan |
| Lilly USA, LLC | $795.99 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.77 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $658.84 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $656.80 | 2024-2025 | Voquezna |
| Allergan, INC. | $600.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $499.23 | 2019-2025 | Gardasil 9, M-M-R II, Verquvo |
| Lundbeck LLC | $496.80 | 2022-2025 | Rexulti |
| Antares Pharma, INC. | $483.30 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $458.22 | 2019-2025 | Tezspire, Aimovig |
| Takeda Pharmaceuticals U.S.A., INC. | $443.56 | 2019-2025 | Trintellix |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamiel Ambrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.